Compare · PEPG vs SRPT

PEPG vs SRPT

Side-by-side comparison of PepGen Inc. (PEPG) and Sarepta Therapeutics Inc. (SRPT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PEPG and SRPT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • SRPT is the larger of the two at $1.52B, about 4.1x PEPG ($370.4M).
  • PEPG has been more active in the news (12 items in the past 4 weeks vs 8 for SRPT).
  • SRPT has more recent analyst coverage (25 ratings vs 6 for PEPG).
MetricPEPGSRPT
Company
PepGen Inc.
Sarepta Therapeutics Inc.
Price
-
-
Market cap
$370.4M
$1.52B
1M return
+39.26%
-
1Y return
-26.27%
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2022
News (4w)
12
8
Recent ratings
6
25
PEPG

PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

SRPT

Sarepta Therapeutics Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Latest PEPG

Latest SRPT